SANCTURA XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SANCTURA XR (SANCTURA XR).
Trospium is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, reducing bladder detrusor muscle contractions.
| Metabolism | Minimally metabolized via ester hydrolysis and conjugation; hepatic CYP450 enzymes are not significantly involved. |
| Excretion | Primarily renal excretion (70-80% as unchanged drug and active metabolite); approximately 10% fecal; 5-10% biliary. |
| Half-life | Terminal elimination half-life is approximately 7-10 hours in patients with normal renal function; prolonged to 20-30 hours in moderate to severe renal impairment. |
| Protein binding | Approximately 20-30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.5-2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral extended-release: approximately 25-30% due to first-pass metabolism. |
| Onset of Action | Oral: 1-2 hours for antimuscarinic effects. |
| Duration of Action | 12-24 hours based on extended-release formulation; clinical effects may persist up to 24 hours with regular dosing. |
| Molecular Weight | 392.53 Da |
60 mg orally once daily, taken with a full glass of water at least 1 hour before meals. Extended-release capsule.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | Creatinine clearance 30-60 mL/min: 60 mg orally once daily. Creatinine clearance <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh class A: 60 mg orally once daily. Child-Pugh class B or C: not recommended; no dosage adjustment data available. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | In elderly patients (≥65 years), start at 60 mg orally once daily; monitor for anticholinergic effects and renal function due to age-related decline. |
| 1st trimester | Trospium chloride is a quaternary ammonium compound with low lipophilicity and minimal placental transfer. Animal studies have not shown fetal harm, but no adequate human studies exist. Use only if clearly needed. |
| 2nd trimester | Same as T1: limited human data; no known teratogenic effects in animal models. Risk vs. benefit assessment required. |
| 3rd trimester | Potential for neonatal adverse effects (e.g., anticholinergic symptoms) if used near term. Avoid in late pregnancy unless essential. |
Clinical note
Comprehensive clinical and safety monograph for SANCTURA XR (SANCTURA XR).
| Placental transfer | Minimal to none. Trospium is a quaternary ammonium compound with low lipid solubility and high polarity, resulting in poor placental penetration. |
| Breastfeeding | Trospium is excreted into breast milk in negligible amounts due to its low oral bioavailability and high molecular weight. However, due to lack of robust human data, caution is advised. Monitor infant for anticholinergic effects (e.g., constipation, dry mouth, urinary retention). |
■ FDA Black Box Warning
None.
| Serious Effects |
Urinary retentionGastric retentionUncontrolled narrow-angle glaucomaHypersensitivity to trospium or any component of the formulation
| Precautions | Angioedema, anaphylactic reactions, urinary retention, decreased GI motility, CNS effects (e.g., dizziness, confusion), exacerbation of narrow-angle glaucoma, heat prostration in hot environments. |
| Food/Dietary | Take on an empty stomach. Food, especially high-fat meals, reduces absorption (Cmax decreased by 35%, AUC decreased by 25%). Avoid grapefruit juice as it may increase drug levels (though interaction not formally studied; precaution advised). |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data suggest minimal risk, but infant monitoring recommended. |
| Teratogenic Risk | Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, trospium chloride administered to pregnant rats during organogenesis at doses up to 200 mg/kg/day (approximately 10 times the maximum recommended human dose based on AUC) resulted in decreased fetal weight and increased incidence of skeletal variations. In rabbits, doses up to 200 mg/kg/day (approximately 50 times the MRHD) caused maternal toxicity and increased resorptions. Potential fetal risks are unknown; use only if clearly needed. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and urinary retention due to anticholinergic effects. Assess fetal well-being via ultrasound if used during pregnancy. Monitor for signs of anticholinergic toxicity (e.g., constipation, blurred vision) in the mother. |
| Fertility Effects | In animal studies, trospium chloride administered to male and female rats at doses up to 200 mg/kg/day (approximately 10 times MRHD) did not impair fertility. No human data available. |
| Clinical Pearls |
| SANCTURA XR (trospium chloride) is a quaternary ammonium anticholinergic that does not cross the blood-brain barrier significantly, reducing CNS side effects (e.g., confusion, dizziness). It is primarily excreted unchanged in urine (60%) and feces (40%). Avoid use in patients with severe renal impairment (CrCl <30 mL/min) due to increased systemic exposure. Drug interactions: Use with other anticholinergics may increase anticholinergic effects; take on an empty stomach (1 hour before meals) to maximize absorption. Dose elderly cautiously due to potential anticholinergic side effects. |
| Patient Advice | Take SANCTURA XR on an empty stomach, at least 1 hour before a meal. · Swallow the capsule whole; do not crush, chew, or open. · May cause dry mouth, constipation, blurred vision, or urinary retention; report difficulty urinating. · Avoid alcohol or CNS depressants that may increase drowsiness or dizziness. · Do not drive or operate machinery until you know how the drug affects you. · Store at room temperature away from moisture and heat. |